Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma

No trials have compared cabozantinib and regorafenib for the second-line treatment of advanced hepatocellular carcinoma (HCC). Conduct a matching-adjusted indirect comparison (MAIC) of the efficacy and safety of second-line cabozantinib and regorafenib in patients with advanced HCC and disease progression after prior sorafenib. The CELESTIAL and RESORCE trials were used for indirect comparison of second-line cabozantinib and regorafenib in...